Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program


You May Also Like

Dynavax to Present at the 2018 Cantor Global Healthcare Conference

BERKELEY, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced ...

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and ...